anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Severity of allergic reactions are highly variable from one individual to another, they can range from absent to life threatening. Allergic manifestations and specifically those of anaphylactic reactions are generally attributed to an IgE-dependent activation of mast cells and/or basophils followed by the release of histamine. Recently however evidence accumulated that other pathways might similarly contribute or even trigger anaphylaxis. Moreover, while the variance in human populations is an important subject to scientific research, medical practices and public health policies typically take a 'one for all' approach to disease management and drug development. Indeed, individual heterogeneity in the immune response can have a big impact on the likelihood to respond to therapy. Because of the complexity of immune responses in the individual and within the population, it has not been possible thus far to define the parameters (genetic or environmental) that define the immune system of allergic patients and its natural occurring variability. Thanks to the efforts that have been made in the framework of the Labex "Milieu Intérieur" study genetic, immunological and environmental factors have been identified that can be linked to the heterogeneity of immune responses in healthy individuals. By comparing these already available data to a novel cohort of patients with defined severe allergic manifestations, we will be able to identify for the first time immunological and environmental parameters that are common to patients with severe allergies and identify those parameters that distinguish allergic patients from the healthy donor cohort. This analysis will thus open new perspectives on deregulated immune pathways in allergic patients allowing to orient future treatment approaches. Furthermore, comparing immune responses before and after allergen-specific immunotherapy will help understanding, which changes in immune responses are causal to a successful treatment. Importantly, this analysis will shed light on the individual differences that may predict the outcome of treatment approaches and propose novel markers of its success. Hence, it will give important insights for the individually adapted treatment of patients.
The invention relates to a system for monitoring a patient's physiological signals and associated devices. Signals are transmitted wirelessly between the battery powered data acquisition subsystem (which also stores the data for later transmission if the wireless link is unavailable) and the host system which has a standard Microsoft Windows Graphical User Interface. The system also allows transmission of control signals from the host system to the data acquisition sub-system. Bluetooth technology, utilised for the digital transmission and encryption of data, will also form the foundation for the automatic detection of host proposed for the system. It has application in ambulatory or static studies in hospitals, clinics or elsewhere, providing wireless connectivity of medical devices allowing systems to be configured and located to suit patients and care staff. Embodiments detail a urine flowmeter, a urodynamics system, a gastro-intestinal motility system and an ano-rectal manometry system.
<P>PROBLEM TO BE SOLVED: To obtain an ophthalmic preparation which can give a refreshing feeling over a long time and can refresh tired eyes.  <P>SOLUTION: This ophthalmic preparation comprises a refreshing ingredient and a thickening agent, and has an absolute viscosity of 3 to 15 mPa s at a temperature of 20°C. The refreshing ingredient can include essential oil ingredients (menthol, and the like) and essential oils. The thickening agent can include ethylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose, polyvinylpyrrolidone, dextran, cyclodextrin, and polyoxyethylene polyoxypropylene block copolymer. When such the ophthalmic preparation is applied, the refreshing feeling can be kept over a long time to enhance the compliance of a user.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
The present invention relates to a Chinese herbal medicine for treating lumbar intervertebral disc protrusion and hyperosteogeny, which is mainly used for curing lumbar intervertebral disc protrusion, cervical spondylopathy and hyperosteogeny. The Chinese herbal medicine comprises 49 pure natural Chinese herbal medicines of peach kernel, safflower, notoginseng, trigone, fructus corni, fructus psopaleae, broomrape, cynomorium, eucommia bark, longspur epimedium, etc., and has a scientific, reasonable, unique and effective formula. The Chinese herbal medicine has the functions of dredging the channels, removing blood stasis, tonifying qi and blood, nouishing the liver and the kidney, warming kidney to invigorate yang, regulating menstruation, nourishing yin, expelling pathogenic cold from channels, clearing heat and drying damp, dispelling wind, relieving convulsion and spasm, dispelling wind and eliminating dampness, and concentrating pain and numbness. By using the Chinese herbal medicine, the capillaries of an affected part are expanded, the blood circulation and the lymph venous return are quickened, and thus, the functions of relieving inflammation, reducing edema and promoting recovery of functions of local tissues are performed. Aseptic inflammation of soft tissues around the hyperplastic spur is quickly eliminated. By using the Chinese herbal medicine, intervertebral disc protrusion, bulge and spur shrink and disappear, and the stenosis of the intervertebral foramen is treated. The Chinese herbal medicine has the advantages of simple decoction, convenient administration of patients and high safety and reliability. Diseases can be cured by the medicine, and the cure rate reaches more than 90 %.
OBJECTIVES: Lung cancer is one of the malignant tumors that threaten human health seriously. Long non-coding RNA (lncRNA) is an important factor affecting tumorigenesis and development. However, the mechanism of lncRNA in lung cancer progression remains to be further explored.
METHODS: In this study, the TCGA database was analyzed, and LINC01572 was found to be increased in lung adenocarcinoma (LUAD) tissues. Thereafter, with the help of databases including lncBase, TargetScan, and mirDIP, as well as Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis, LINC01572/miRNA-338-5p/TTK regulatory axis and downstream p53 signaling pathway were excavated. qRT-PCR was adopted to detect levels of LINC01572, miRNA-338-5p, and TTK in LUAD cells. The role that LINC01572 played in LUAD cells was validated by CCK-8 assay, flow cytometry, colony formation, Transwell, and scratch healing assays. The binding ability between LINC01572/TTK and miRNA-338-5p was then verified by dual-luciferase and RIP analysis.
KEY FINDINGS: The results of this study demonstrated that LINC01572 was elevated in LUAD cells compared with normal cells. The overexpression of LINC01572 promoted the proliferative and migratory properties of LUAD cells but inhibited cell apoptosis. The inhibition of LINC01572 resulted in the opposite result. In addition, rescue experiments revealed that LINC01572, as a molecular sponge of miRNA-338-5p, targeted TTK to manipulate p53 for facilitating LUAD cell malignant progression. Apart from this, we constructed a mouse xenograft model and confirmed that the knockdown of LINC01572 hindered the growth of LUAD solid tumors in vivo.
CONCLUSIONS: Our findings illuminated the molecular mechanism of LINC01572 influencing LUAD and provided new insights for targeted therapy of LUAD cells.
Patients will receive transcranial direct current stimulation using an adaptive protocol allowing for doses of 0 to 4 mA during the course of the treatment, with twenty 20-minute sessions over the course of 4 to 6 weeks. Treatments will take place daily, 5 days per week.
HIV-infected patients may develop a condition known as HIV-Associated Motor / Cognitive Complex (also known as AIDS dementia complex) that causes damage to the nervous system, particularly the brain and spinal cord. Evidence exists that nimodipine protects nerve cells in culture from injury by HIV. Although nimodipine has been used in patients with other neurological problems, its safety and effectiveness in halting the progression of HIV-Associated Motor / Cognitive Complex is not yet known.

Forty patients currently taking zidovudine (AZT) or any other approved antiretroviral agent will be randomized to one of three treatment arms: high-dose nimodipine, low-dose nimodipine, or placebo. Additionally, six patients who are intolerant to standard antiretroviral therapy will be randomized to receive high- or low-dose nimodipine. Nimodipine is administered by mouth concurrently with patients' prestudy dose of antiretroviral agent. Treatment is given for 16 weeks, and patients are followed every 4 weeks. As an option, all patients may receive an additional 16 weeks of low-dose nimodipine.
The improved efficacy and generally favorable safety profile of recently approved and emerging antiobesity medications (AOMs), which result in an average weight reduction of ≥15%, represent significant advancement in the treatment of obesity. This narrative review aims to provide practical evidence-based recommendations for nutritional assessment, management, and monitoring of patients treated with AOMs. Prior to treatment, clinicians can identify preexisting nutritional risk factors and counsel their patients on recommended intakes of protein, dietary fiber, micronutrients, and fluids. During treatment with AOMs, ongoing monitoring can facilitate early recognition and management of gastrointestinal symptoms or inadequate nutrient or fluid intake. Attention should also be paid to other factors that can impact response to treatment and quality of life, such as physical activity and social and emotional health. In the context of treatment with AOMs, clinicians can play an active role in supporting their patients with obesity to improve their health and well-being and promote optimal nutritional and medical outcomes.
Participants receive osimertinib orally at a dose of 80mg daily for a 28-day treatment period. After the start of treatment, cerebrospinal fluid is collected every 12 weeks for circulating tumor cell (CTC) examination and routine cytopathological assessment. If the routine cytopathological test is positive, participants are sequentially treated with continued osimertinib at 80mg daily, in combination with bevacizumab administered intravenously at a dosage of 7.5mg/kg of body weight, on the first day of each cycle, with medication given once every 3 weeks. A continuous treatment of 21 days constitutes one treatment cycle. After the initiation of treatment, cerebrospinal fluid is collected every 6 weeks for CTC testing and routine cytopathological examination.
Pharmaceutical compositions are disclosed including an effective amount of a fusion protein that contains an anchor domain and a therapeutic polypeptide for use in treating a disorder that affects the eye ( e.g. , corneal haze or scarring, dry eye disease, and inflammation of an ocular surface). Fusion proteins are disclosed that includes an anchor domain and a therapeutic polypeptide. Some embodiments include an isolated nucleic acid molecule that can encode the fusion protein. Methods are also disclosed for treating a subject with a disorder that affects the eye ( e.g. , corneal haze or scarring, dry eye disease, and inflammation of an ocular surface) that includes administering to the eye of the subject a therapeutically effective amount of the fusion protein disclosed herein.
FIELD: medicine, cardiology. SUBSTANCE: invention relates to treatment of paroxysms in supraventricular tachycardia. Method involves intravenous administration of relanium in the mean therapeutic dose followed by administration of one of agonist preparations of adenosine receptors, for example, adenosine or ATP. Method ensures to reduce therapy complications and probability of disease relapse. EFFECT: improved method of treatment. 1 ex
Fluticasone propionate demonstrated no tumorigenic potential in mice at oral doses up to 1,000 mcg/kg (approximately 20 times the maximum recommended daily intranasal dose in adults and approximately 10 times the maximum recommended daily intranasal dose in children on a mcg/m basis) for 78 weeks or in rats at inhalation doses up to 57 mcg/kg (approximately 2 times the maximum recommended daily intranasal dose in adults and approximately equivalent to the maximum recommended daily intranasal dose in children on a mcg/m basis) for 104 weeks. 22

Fluticasone propionate did not induce gene mutation in prokaryotic or eukaryotic cells in vitro. No significant clastogenic effect was seen in cultured human peripheral lymphocytes in vitro or in the mouse micronucleus test.

No evidence of impairment of fertility was observed in reproductive studies conducted in male and female rats at subcutaneous doses up to 50 mcg/kg (approximately 2 times the maximum recommended daily intranasal dose in adults on a mcg/m basis). Prostate weight was significantly reduced at a subcutaneous dose of 50 mcg/kg. 2
Method for obtaining peptides and fusion recombinant proteins from the VP2 sub-unit of canine parvovirus (CPV), and its use in methods of diagnosis and the formulation of vaccines. These proteins are obtained by culturing E. Coli cells transformed with DNA coding for the recombinant VP2 protein of CPV under conditions which enable its expression. These proteins can be used for the formulation of vaccines and to detect the presence of anti-CPV antibodies. For this a sample of a biological fluid from an animal is placed in contact with the recombinant VP2 protein of CPV, a specific antibody for the anti-CPV antibody bound to a marker is added, and the presence of the said antibodies is detected by reaction between the marker and a suitable substrate. In addition to this, a peptide which can be used in the formulation of vaccines has been identified using the said recombinant proteins and specific monoclonal antibodies for the virus. The proteins in this invention have application in veterinary practice.
Pts with morphologic evidence of disease at the time of T cell infusion, (≥5% blasts in the bone marrow) as assessed by morphology or flow cytometry. Participating site PI to determine cohort stratification in the event of morphology/flow cytometry blast count discrepancy. Pts with increased blasts (5-10% blasts) that are immunophenotypically consistent with recovering marrow from prior re-induction chemo may be treated under Cohort 1 with approval of the participating site PI. Cohort 2 pts will get conditioning chemo followed by 1x10\^6 19-28z+ T cells/kg over 1 to 2 days. During formulation of EOP T cells, under or over estimation of CAR modified T-cells may occur. Pts may get up to 35% over total cell dose with approval by the participating site PI. Both cohorts, pts will be allowed to receive a 2nd treatment of 19-28z+ T cells if they benefited from the first infusion \& did not experience any non-hematologic grade 4 toxicities.
The present invention relates to the field of food, which is health care food with an antihypelipidemic and antihyperglycemic function. The health care food comprises the components of the following proportion by weight: 85 to 115 of amorphophallus konjac, 68 to 92 of balsam pear, 51 to 69 of wolfberry fruit, 34 to 46 of astragalus root and 17 to 23 of ginseng. The health care food is prepared by raw material processing and preparation. The health care food is processed by adopting traditional dietetic therapy and modern nanotechnology. The health care food is proportioned by a rational diet forming mode. The present invention uses an advanced production technology and reserves the original peculiar natural quality and efficacy. The health care food contains natural plant insulin bioactivity, various proteins, various vitamins, trace elements (selenium, zinc, etc.) and plant vitamins. Thus, the present invention is rich in nutrition, and has the functions of sugar and lipid decrease, cholesterol decrease, pressure reduction, channel activation, skin nourishing and moistening and detoxification. Thus, the health care food enhances the immune function of human bodies, and is best suitable for diabetics, anti-aging persons, etc.
Geriatric Use:Patients over 65 years, particularly those with hypertension, may be at increased risk for developing hypotension while undergoing anesthesia with MARCAINE. (See ADVERSE REACTIONS.) 

Elderly patients may require lower doses of MARCAINE. (See PRECAUTIONS, Epidural Anesthesiaand DOSAGE AND ADMINISTRATION.) 

In clinical studies, differences in various pharmacokinetic parameters have been observed between elderly and younger patients. (See CLINICAL PHARMACOLOGY.) 

This product is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function. (See CLINICAL PHARMACOLOGY.)
Novel peptide sequences homologous to the known fibrinogen derived haptotactic peptides, C.beta. and C.alpha.E, are disclosed. The novel peptides are derived from proteins related or unrelated to fibrinogen including a peptide adjacent to fibrinogen .gamma.-chain C terminus denoted pre-C.gamma. as well as isotypes of angiopoietin, human microfibril-associated glycoprotein (mfap) and tenascins. Novel peptides having significant homology to the known fibrinogen derived haptotactic peptides are now shown to possess cell attraction activities. Active fragments comprising shorter 8-10 mer peptides are also disclosed, and shown to elicit significant haptotactic activity from a variety of cells, such as fibroblasts, endothelial and smooth muscle cells. The homologous peptides disclosed permit delineation of consensus sequences for haptotactic activity. The peptides are useful in pharmaceutical compositions alone or in conjunction with a medical device or implant.
Tretinoin is a naturally occurring vitamin A metabolite that participates in many biological processes. It is not a cytolytic agent but instead induces cytodifferentiation and decreased proliferation of APL cells achieving complete remission (CR). In addition, ATRA and similar retinoids were also discovered to have significant immune-modulating activities towards Myeloid derived suppressor cells (MDSCs) that contribute greatly to cancer growth and progression. Preclinical efficacies of HF1K16 to induce MDSC differentiation into dendritic cells (DCs) and downregulate their inhibitory effects on cytotoxic T cell activities against cancer have been demonstrated.

HF1K16 is a pegylated liposome formulation of tretinoin developed for improved PK behavior, higher therapeutic index, and more specific targeted mechanism towards MDSCs. The objectives of this study are to assess the safety and tolerability of HF1K16. The ATRA pharmacokinetic parameters will be determined with correlations to the liposome doses administered.
BACKGROUND: Chronic hypoxia and skeletal muscle atrophy commonly coexist in patients with COPD and CHF, yet the underlying physio-pathological mechanisms remain elusive. Muscle regeneration, driven by muscle stem cells (MuSCs), holds therapeutic potential for mitigating muscle atrophy. This study endeavours to investigate the influence of chronic hypoxia on muscle regeneration, unravel key molecular mechanisms, and explore potential therapeutic interventions.
METHODS: Experimental mice were exposed to prolonged normobaric hypoxic air (15% pO2, 1 atm, 2 weeks) to establish a chronic hypoxia model. The impact of chronic hypoxia on body composition, muscle mass, muscle strength, and the expression levels of hypoxia-inducible factors HIF-1α and HIF-2α in MuSC was examined. The influence of chronic hypoxia on muscle regeneration, MuSC proliferation, and the recovery of muscle mass and strength following cardiotoxin-induced injury were assessed. The muscle regeneration capacities under chronic hypoxia were compared between wildtype mice, MuSC-specific HIF-2α knockout mice, and mice treated with HIF-2α inhibitor PT2385, and angiotensin converting enzyme (ACE) inhibitor lisinopril. Transcriptomic analysis was performed to identify hypoxia- and HIF-2α-dependent molecular mechanisms. Statistical significance was determined using analysis of variance (ANOVA) and Mann-Whitney U tests.
RESULTS: Chronic hypoxia led to limb muscle atrophy (EDL: 17.7%, P < 0.001; Soleus: 11.5% reduction in weight, P < 0.001) and weakness (10.0% reduction in peak-isometric torque, P < 0.001), along with impaired muscle regeneration characterized by diminished myofibre cross-sectional areas, increased fibrosis (P < 0.001), and incomplete strength recovery (92.3% of pre-injury levels, P < 0.05). HIF-2α stabilization in MuSC under chronic hypoxia hindered MuSC proliferation (26.1% reduction of MuSC at 10 dpi, P < 0.01). HIF-2α ablation in MuSC mitigated the adverse effects of chronic hypoxia on muscle regeneration and MuSC proliferation (30.9% increase in MuSC numbers at 10 dpi, P < 0.01), while HIF-1α ablation did not have the same effect. HIF-2α stabilization under chronic hypoxia led to elevated local ACE, a novel direct target of HIF-2α. Notably, pharmacological interventions with PT2385 or lisinopril enhanced muscle regeneration under chronic hypoxia (PT2385: 81.3% increase, P < 0.001; lisinopril: 34.6% increase in MuSC numbers at 10 dpi, P < 0.05), suggesting their therapeutic potential for alleviating chronic hypoxia-associated muscle atrophy.
CONCLUSIONS: Chronic hypoxia detrimentally affects skeletal muscle regeneration by stabilizing HIF-2α in MuSC and thereby diminishing MuSC proliferation. HIF-2α increases local ACE levels in skeletal muscle, contributing to hypoxia-induced regenerative deficits. Administration of HIF-2α or ACE inhibitors may prove beneficial to ameliorate chronic hypoxia-associated muscle atrophy and weakness by improving muscle regeneration under chronic hypoxia.
Continuous epidural infusion of 5 ml / hour + patient controlled extra boluses of 5 ml, maximum 3 / hour. Medicine solution is bupivacaine 1 mg/ml, fentanyl 2 mcg/ml, adrenaline 2 mcg/ml.
OBJECTIVE: This study aimed to evaluate the technical variations of one-anastomosis gastric bypass (OAGB) among IFSO-APC and MENAC experts.
BACKGROUND: The multitude of technical variations and patient selection challenges among metabolic and bariatric surgeons worldwide necessitates a heightened awareness of these issues. Understanding different perspectives and viewpoints can empower surgeons performing OAGB to adapt their techniques, leading to improved outcomes and reduced complications.
METHODS: The scientific team of IFSO-APC, consisting of skilled bariatric and metabolic surgeons specializing in OAGB, conducted a confidential online survey. The survey aimed to assess technical variations and considerations related to OAGB within the IFSO-APC and IFSO-MENAC chapters. A total of 85 OAGB experts participated in the survey, providing their responses through a 35-question online format. The survey took place from January 1, 2024, to February 15, 2024.
RESULTS: Most experts do not perform OAGB for children and adolescents younger than 18 years. Most experts create the gastric pouch over a 36-40-F bougie and prefer to create a gastrojejunostomy, at the posterior wall of the gastric pouch. An anti-reflux suture during OAGB is performed in all patients by 51.8% of experts. Most experts set a common limb length of > 4 m in revisional and conversional OAGBs to prevent nutritional complications.
CONCLUSION: The ongoing debate among metabolic and bariatric surgeons regarding the technical variations and patient selection in OAGB remains a significant point of discussion. This survey demonstrated the variations in technical aspects and patient selection for OAGB among MBS surgeons in the IFSO-APC and IFSO-MENAC chapters. Standardizing the OAGB technique is crucial to ensure optimal safety and efficacy in this procedure.